Free Trial
OTC:CMOPF

Cosmo Pharmaceuticals (CMOPF) Stock Price, News & Analysis

Cosmo Pharmaceuticals logo
C$62.80 +0.01 (+0.02%)
As of 03/31/2025 03:38 PM Eastern

About Cosmo Pharmaceuticals Stock (OTC:CMOPF)

Key Stats

Today's Range
C$62.80
C$62.80
50-Day Range
C$62.79
C$76.00
52-Week Range
C$62.79
C$95.00
Volume
20 shs
Average Volume
192 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Remove Ads
Receive CMOPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cosmo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CMOPF Stock News Headlines

Cosmo Pharmaceuticals publishes Annual Report 2024
Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Cosmo Pharmaceuticals reports FY results
See More Headlines

CMOPF Stock Analysis - Frequently Asked Questions

Cosmo Pharmaceuticals' stock was trading at C$66.93 at the beginning of the year. Since then, CMOPF shares have decreased by 6.2% and is now trading at C$62.80.
View the best growth stocks for 2025 here
.

Shares of CMOPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTC
Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
OTC:CMOPF
CIK
N/A
Fax
N/A
Employees
319
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (OTC:CMOPF) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners